BEDFORD, Mass., Aug. 7, 2025 /PRNewswire/ -- Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced premarket approval (PMA) from the U.S. Food and Drug Administration...
BEDFORD, Mass., Aug. 7, 2025 /PRNewswire/ -- Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced premarket approval (PMA) from the U.S. Food and Drug Administration...
BEDFORD, Mass., Aug. 7, 2025...